Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights
$24,750.00   |  '

Congenital Heart Block – Executive Insights – Congenital Heart Block | Executive Insights | US/EU5 | 2022

Login to access report north_east
Buy report north_east

Congenital heart block (CHB), also known as atrioventricular block, is a rare heart block disorder in which maternal antibodies attack the impulse-generating heart muscles of fetuses and newborns. Minimizing the deterioration of heart muscles and preventing disease progression are the key treatment goals in CHB. No therapies are approved for CHB, and patients are managed with off-label drugs such as dexamethasone and IVIG, or through plasmapheresis and pacemaker implantation. In addition, no commercial pharmacotherapies are in the pipeline for CHB. A major unmet need is for effective therapies and represents a commercial opportunity for drug developers in this market.

QUESTIONS ANSWERED

  • What is the diagnosed incidence of CHB?
  • What is the current market landscape including the diagnostic and management practices
  • What are the current therapy and emerging therapy landscapes?
  • What is the estimated cost of treatment in different geographies?
  • What are the key unmet needs in the management of CHB?
  • What are the key market drivers and limiters?
  • What are the opinions of KOLs on different aspects of CHB?

PRODUCT DESCRIPTION

Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.

GEOGRAPHY: United States, EU5

PRIMARY RESEARCH: 13 KOL interviews from November 2021 to January 2022

KEY DRUGS COVERED: Dexamethasone, intravenous immune globulin (IVIG)

Table of contents

Buy report north_east
Login to access report north_east

Related Market Assessment Reports

Report
Insomnia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Insomnia (US)
Insomnia is a prevalent sleep disorder characterized by daytime dysfunction resulting from one or more sleep problems. The treatment of insomnia is highly individualized, and physicians consider…
north_east
Report
Psoriasis – Geographic Focus: China – Psoriasis | China In-Depth | China | 2025
Psoriasis is a chronic dermatologic condition with rising prevalence in China, particularly in urban areas where heightened awareness and improved access to care have led to higher diagnosis rates…
north_east
Report
Type 2 Diabetes – Geographic Focus: China – Type 2 Diabetes – China In-Depth (China)
In China, type 2 diabetes (T2D) continues to be a leading public health concern, with the highest global prevalence. Biguanides continue to dominate the market, but the use of SGLT-2 inhibitors and…
north_east
Report
Chronic Kidney Disease – Geographic Focus: China – Chronic Kidney Disease – China In-Depth (China)
Chronic kidney disease (CKD) is an irreversible condition requiring lifelong management. In China, CKD is notably widespread, particularly among older adults and those with chronic risk factors…
north_east
Report
Eosinophilic Esophagitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Eosinophilic Esophagitis (US)
Eosinophilic esophagitis (EoE) is a chronic allergic inflammatory condition of the esophagus, marked by an accumulation of eosinophils. This can lead to difficulty swallowing and potentially…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east